Akili, Inc. (AKLI)
Jul 2, 2024 - AKLI was delisted (reason: acquired by Virtual Therapeutics)
0.4331
+0.0010 (0.25%)
Inactive · Last trade price on Jul 1, 2024

Company Description

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies.

The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases.

It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization.

The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Akili, Inc.
Akili logo
CountryUnited States
Founded1997
IndustryHealth Information Services
SectorHealthcare
Employees68
CEOMatthew Franklin M.B.A.

Contact Details

Address:
71 Commercial Street, Mailbox 312
Boston, Massachusetts 02109
Phone617-456-0597
Websiteakiliinteractive.com

Stock Details

Ticker SymbolAKLI
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001850266
CUSIP Number00974B107
ISIN NumberUS00974B1070
Employer ID92-3654772
SIC Code3841

Key Executives

NamePosition
Matthew Franklin M.B.A.President, Chief Executive Officer and Director
Dr. Walter Edward Martucci II, Ph.D.Co-Founder and Chairman
Dr. Adam Gazzaley M.D., Ph.D.Co-Founder, Chief Science Advisor and Director
Jacqueline L. Studer J.D.Chief Legal Officer, General Counsel and Secretary
Caty ReidVice President of Marketing and Communications
Dr. Scott H. Kollins Ph.D.Chief Medical Officer
Jonathan DavidChief Product Officer

Latest SEC Filings

DateTypeTitle
Jul 2, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 2, 2024S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jul 2, 2024POS AMPost-Effective amendments for registration statement
Jul 2, 20248-KCurrent Report
Jul 2, 2024SC 14D9/AFiling
Jul 2, 202425-NSEFiling
Jul 2, 2024SC TO-T/AFiling
Jun 18, 20248-KCurrent Report
Jun 10, 2024SC 13GStatement of acquisition of beneficial ownership by individuals
Jun 5, 2024SC 14D9Filing